Volume 10, Number 11—November 2004
Research
Histopathologic Improvement with Lymphedema Management, Léogâne, Haiti
Table 2
Location in skin | Histopathologic characteristic | Control (N = 26) n (%) | Lymphedema |
||
---|---|---|---|---|---|
Stage 1 (N = 12) n (%) | Stage 2 (N = 60) n (%) | Stage 3 (N = 20) n (%) | |||
Epidermis | Hyperkeratosis | 4 (15) | 5 (42) | 23 (38)a | 16 (80)b |
Hypergranulosis | 0 (0) | 1 (8) | 5 (8) | 4 (20)a | |
Acanthosis | 0 (0) | 3 (25)a | 11 (18)a | 6 (30)c | |
Superficial dermis | Fibrolamellar hyperplasia | 5 (19) | 6 (50) | 25 (42)a | 11 (55)a |
Condensed collagen | 0 (0) | 1 (8) | 18 (30)c | 7 (35)c | |
Perivascular fibrosis | 0 (0) | 1 (8) | 6 (10) | 3 (15) | |
Perivascular infiltrate | |||||
Acute | 0 (0) | 0 (0) | 2 (3) | 0 (0) | |
Chronic | 11 (42) | 8 (67) | 46 (77)c | 19 (95)b | |
Pronounced intensity | 1 (4) | 2 (17) | 11 (18) | 7 (35)c | |
Presence of plasma cells | 0 (0) | 0 (0) | 9 (15)a | 6 (30)c | |
Deep dermis | Perivascular fibrosis | 3 (11) | 1 (8) | 16 (27) | 8 (40)a |
Perivascular infiltrate | |||||
Acute | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Chronic | 12 (46) | 6 (50) | 54 (90)b | 19 (95)b | |
Pronounced intensity | 1 (4) | 3 (25) | 20 (33)c | 11 (55)b | |
Presence of plasma cells | 1 (4) | 7 (58)b | 37 (62)b | 15 (75)b | |
Periadnexal infiltrate | |||||
Acute | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Chronic | 4 (15) | 4 (33) | 36 (60)b | 11 (55)c | |
Pronounced intensity | 0 (0) | 0 (0) | 10 (17)a | 3 (15) | |
Subcutaneous tissue | Infiltrate in fibrous septa | ||||
Acute | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Chronic | 1 (4) | 3 (25) | 19 (32)c | 9 (45)c | |
Pronounced intensity | 1 (4) | 3 (25) | 5 (8) | 3 (15) |
ap < 0.05 (compared to control leg biopsy specimens).
bp < 0.001 (compared to control leg biopsy specimens).
cp < 0.01 (compared to control leg biopsy specimens).
Page created: April 22, 2011
Page updated: April 22, 2011
Page reviewed: April 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.